Crucell NV said that it has reached an agreement with GlaxoSmithKline Biologicals to combine their vaccine technologies to produce a second generation vaccine for people at risk of malaria. Financial terms were not disclosed. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
